MedTrace Logo

Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia

NCT01898338 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2018-01-17

No results posted yet for this study

Summary

To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin alone in the treatment of methicillin resistant Staphylococcus aureus (MRSA) bacteremia.

Conditions

  • Staph Aureus Methicillin Resistant Bacteremia

Interventions

DRUG

Fosfomycin 2gr/6h iv

DRUG

Daptomycin 10mg/kg/24h iv

Sponsors & Collaborators

  • Hospital Universitari de Bellvitge

    collaborator OTHER

  • Miquel Pujol

    lead OTHER

Principal Investigators

  • Miquel Pujol, MD, PhD · (Infectious Diseases Service) Hospital Universitari de Bellvitge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2018-01-10
Completion
2018-01-10

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01898338 on ClinicalTrials.gov